Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Adrenomed AG
Headquarters: Hennigsdorf, Germany
Website: http://www.adrenomed.com
Year Founded: 2009
Status: Private
BioCentury | Mar 16, 2022
Management Tracks
Lilly veteran Smiley to join Zai as COO
Plus Dias becomes CMO at Coherus, updates from Illumina, Metagenomi, Adrenomed, Epizyme, Garuda and more
BioCentury | Apr 27, 2021
Deals
German plays deliver on data, plus accelerated approval on trial: a BioCentury podcast
A pair of biotechs have endured the rocky financing landscape in their home country of Germany for over a decade to deliver standout data this month. On the latest BioCentury This Week podcast,
BioCentury | Apr 22, 2021
Product Development
Adrenomed looks to bring precision medicine to sepsis
German biotech prepares to fund-raise on the back of Phase II data
BioCentury | Dec 1, 2020
Product Development
Nov. 30 Quick Takes: Grail piloting blood test in U.K.; plus Rhythm, Kadmon, venture rounds for Adrenomed, Xbiome, Transition
Grail piloting cancer blood test with NHS EnglandGrail Inc. announced a pilot program with NHS England using the company's Galleri blood test to monitor 140,000 asymptomatic participants aged 50
BioCentury | Nov 1, 2019
Product Development
Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention
Adrenomed is braving the difficult field of sepsis by targeting a previously untapped downstream mechanism.
Items per page:
1 - 6 of 6